Рет қаралды 195
During the AML Hub Steering Committee meeting, held on November 15, 2023, key opinion leaders met to discuss which patients should be considered for allogenic hematopoietic stem cell transplantation. This discussion was chaired by Charles Craddock and featured Jefferey Lancet, Roland Walter, Jorge Sierra, Gail Roboz, and Gert Ossenkoppele.
Charles Craddock discussed the optimization of transplant outcomes and highlighted key data from several recent studies. The steering committee considered factors that may impact transplant outcomes and the need to optimize patient status before transplant. They also discussed treatment decisions in older/unfit patients and explored factors to consider when deciding whether to proceed to transplant or pursue ongoing maintenance therapy.